Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis

References

• KinoTTissue glucocorticoid sensitivity: beyond stochastic regulation on the diverse actions of glucocorticoidsHorm Metab Res200739642042417578758
   PubMed Web of Science ®Google Scholar
• ViegasLRHoijmanEBeatoMPecciAMechanisms involved in tissue-specific apopotosis regulated by glucocorticoidsJ Steroid Biochem Mol Biol20081093–527327818424036
   PubMed Web of Science ®Google Scholar
• BaxterJDRousseauGGGlucocorticoid Hormone Action: an overviewMonogr Endocrinol197912124386083
   PubMedGoogle Scholar
• ColeTJBlendyJAMonaghanAPTargeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturationGenes Dev1995913160816217628695
   PubMed Web of Science ®Google Scholar
• BergerSBleichMSchmidWMineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolismProc Natl Acad Sci U S A19989516942494299689096
   PubMed Web of Science ®Google Scholar
• McCabeBFAutoimmune sensorineural hearing lossAnn Otol Rhinol Laryngol1979885 Pt 1585589496191
   PubMed Web of Science ®Google Scholar
• DodsonKMSismanisAIntratympanic perfusion for the treatment of tinnitusOtolaryngol Clin North Am2004375991100015474106
   PubMed Web of Science ®Google Scholar
• DodsonKMWoodsonESismanisAIntratympanic steroid perfusion for the treatment of Ménière’s disease: a retrospective studyEar Nose Throat J200483639439815266874
   PubMedGoogle Scholar
• TaitASButtsCLSternbergEMThe role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious diseaseJ Leukoc Biol200884492493118664528
   PubMed Web of Science ®Google Scholar
• TruneDRKemptonJBHarrisonARWobigJLGlucocorticoid impact on cochlear function and systemic side effects in autoimmune C3.MRL-Faslpr and normal C3H/HeJ miceHear Res20072261–220921717098384
   PubMed Web of Science ®Google Scholar
• CanalisEBilezikianJPAngeliAGiustinaAPerspectives on glucocorticoid-induced osteoporosisBone200434459359815050888
   PubMed Web of Science ®Google Scholar
• BaltzanMASuissaSBauerDCCummingsSRHip fractures attributable to corticosteroid useLancet19993539161132710218535
   PubMed Web of Science ®Google Scholar
• CenterJRNguyenTVSchneiderDSambrookPNEismanJAMortality after all major types of osteoporotic fracture in men and women: an observational studyLancet199935391651707
   Google Scholar
• CooperCCouplandCMitchellMRheumatoid arthritis, corticosteroid therapy and hip fractureAnn Rheum Dis199554149527880122
   PubMed Web of Science ®Google Scholar
• ReidIRGlucocorticoid osteoporosis – mechanisms and managementEur J Endocrinol199713732092179330580
   PubMed Web of Science ®Google Scholar
• McIlwainHHGlucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and managementPrev Med200336224324912591000
   PubMed Web of Science ®Google Scholar
• DelanyAMDongYCanalisEMechanisms of glucocorticoid action in bone cellsJ Cell Biochem19945632953027876321
   PubMed Web of Science ®Google Scholar
• van StaaTPThe pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosisCalcif Tissue Int200679312913716969593
   PubMed Web of Science ®Google Scholar
• CurtisJRWestfallAOAllisonJJLongitudinal patterns in the prevention of osteoporosis in glucocorticoid treated patientsArthritis Rheum200552814851494
   Google Scholar
• CurtisJRWestfallAOAllisonJChallenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trialArch Intern Med2007167659159617389291
   PubMedGoogle Scholar
• de NijsRNJacobsJWLemsWFAlendronate or alfacalcidol in glucocorticoid-induced osteoporosisN Engl J Med2006355767568416914703
   PubMed Web of Science ®Google Scholar
• van StaaTPGeusensPZhangBLeufkensHGBoonenACooperCIndividual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoidsRheumatology (Oxford)200746346046616899499
   PubMed Web of Science ®Google Scholar
• CohenSLevyRMKellerMRisedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyArthritis Rheum199942112309231810555025
   PubMed Web of Science ®Google Scholar
• ReidDMHughesRALaanRFEfficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment StudyJ Bone Miner Res20001561006101310841169
   PubMed Web of Science ®Google Scholar
• SaagKGEmkeyRSchnitzerTJAlendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study GroupN Engl J Med199833952922999682041
   PubMed Web of Science ®Google Scholar
• CompstonJEEmerging consensus on prevention and treatment of glucocorticoid-induced osteoporosisCurr Rheumatol Rep200791788417437672
   PubMedGoogle Scholar
• CompstonJUS and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differencesCurr Rheumatol Rep200461666914713404
   PubMedGoogle Scholar
• AdlerRAHochbergMCSuggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans AffairsArch Intern Med2003163212619262414638562
   PubMedGoogle Scholar
• WeinsteinRSRobersonPKManolagasSCGiant osteoclast formation and long-term oral bisphosphonate therapyN Engl J Med20093601536219118304
   PubMed Web of Science ®Google Scholar
• RoelofsAJThompsonKGordonSRogersMJMolecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res20061220 Pt 262226230
   Google Scholar
• TanvetyanonTStiffPJManagement of the adverse effects associated with intravenous disphosphonatesAnn Oncol200617689790716547070
   PubMed Web of Science ®Google Scholar
• HamiltonBMcCoyKTaggartHTolerability and compliance with risedronate in clinical practiceOsteoporos Int200314325926212730745
   PubMed Web of Science ®Google Scholar
• CramerJALynchNOGaudinAFWalkerMCowellWThe effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and FranceClin Ther200628101686169417157124
   PubMed Web of Science ®Google Scholar
• CramerJAGoldDTSilvermanSLLewieckiEMA systematic review of persistence and compliance with bisphosphonates for osteoporosisOsteoporos Int20071881023103117308956
   PubMed Web of Science ®Google Scholar
• SeemanECompstonJAdachiJNon-compliance: the Achilles’ heel of anti-fracture efficacyOsteoporos Int200718671171917245547
   PubMed Web of Science ®Google Scholar
• SirisESHarrisSTRosenCJAdherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databasesMayo Clin Proc20068181013102216901023
   PubMed Web of Science ®Google Scholar
• ReidDMDevogelaerJPSaagKZoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trialLancet200937396711253126319362675
   PubMed Web of Science ®Google Scholar
• NancollasGHTangRPhippsRJNovel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatiteBone200638561762716046206
   PubMed Web of Science ®Google Scholar
• DunfordJEThompsonKCoxonFPStructure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonatesJ Clin Pharmacol Exp Ther20012962235242
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyAclasta: summary of product characteristics [online]. April 14, 2010. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/aclasta/aclosta.htm Accessed on April 26, 2010
   Google Scholar
• Food and Drug AdministrationReclast® (zoledronic acid) injection: US prescribing information [online]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021817s001lbl.pdf
   Google Scholar
• BlackDMDelmasPDEastellROnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
   PubMed Web of Science ®Google Scholar
• McClungMReckerRMillerPIntravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronateBone200741112212817468062
   PubMed Web of Science ®Google Scholar
• ChenTBerensonJVescioRPharmacokinetics and phamiacodynamics of zoledronic acid in cancer patients with bone métastasesJ Clin Pharmacol200242111228123612412821
   PubMed Web of Science ®Google Scholar
• LylesKWColon-EmericCSMagazinerJSZoledronic acid and clinical fractures and mortality after hip fractureN Engl J Med2007357181799180917878149
   PubMed Web of Science ®Google Scholar
• BoonenSBlackMDColon-EmericSCEfficacy and safety of a once yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and olderJAGS201058292299
   PubMed Web of Science ®Google Scholar
• ErkisenEFLylesKWColon-EmericCSAntifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fractureJ Bone Miner Res20092471308131319257818
   PubMed Web of Science ®Google Scholar
• HewittRELissinaAGreenAESlayESPriceDASewellAKThe bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statinsClin Exp Immunol2005139110111115606619
   PubMed Web of Science ®Google Scholar
• ContePFGuarneriVSafety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist9Suppl 42004
   Google Scholar
• FraunfelderFWFraunfelderFRJensvoldBScleritis and other ocular side effects associated with pamidronate disodiumAm J Opthalmol135219222
   PubMed Web of Science ®Google Scholar
• ColucciAModoratiGMiserocchiEAnterior uveitis complicating zoledronic acid infusionOcul Immunol Inflamm200917426726819657981
   PubMed Web of Science ®Google Scholar
• MillerPDRouxCBoonenSSafety and efficacy of risedronate in patients with age related reduced renal functions as estimated by the Cockcroft and Gaukt method: a pooled analysis of nine clinical trialsJ Bone Min Res20052021052115
   PubMed Web of Science ®Google Scholar
• LawanskySKomaroffECavanaughPFRelationship between age, renal function and bone mineral density in the US populationOsteoporosis Int200314570576
   PubMed Web of Science ®Google Scholar
• ChennuruSKoduriJBaumannMARisk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acidIntern Med J200838863563718284458
   PubMed Web of Science ®Google Scholar
• MarxRESawatariYFortinMBroumandVBisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatmentJ Oral Maxillofac Surg200563111567157516243172
   PubMed Web of Science ®Google Scholar
• KhoslaSBurrDCauleyJBisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral researchJ Bone Miner Res200722101479149117663640
   PubMed Web of Science ®Google Scholar
• HeckbertSRLiGCummingsSRSmithNLPsatyBMUse of alendronate and risk of incident atrial fibrillation in womenArch Intern Med2008168882683118443257
   PubMedGoogle Scholar
• SorensenHTChristensenSMehnertFUse of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control studyBMJ2000336764881381618334527
   PubMedGoogle Scholar
• KaramRCammJMcClungMYearly zoledronic acid in postmenopausal osteoporosisN Engl J Med2007357771271317703529
   PubMed Web of Science ®Google Scholar